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AbsTrACT
background and aims Serrated polyposis syndrome 
(SPS) is associated with an increased risk of colorectal 
cancer (crc). international guidelines recommend 
surveillance intervals of 1–2 years. However, yearly 
surveillance likely leads to overtreatment for many. We 
prospectively assessed a surveillance protocol aiming to 
safely reduce the burden of colonoscopies.
Methods Between 2013 and 2018, we enrolled 
SPS patients from nine Dutch and Spanish hospitals. 
Patients were surveilled using a protocol appointing 
either a 1- year or 2- year interval after each surveillance 
colonoscopy, based on polyp burden. Primary endpoint 
was the 5- year cumulative incidence of crc and 
advanced neoplasia (an) during surveillance.
results We followed 271 SPS patients for a median of 
3.6 years. During surveillance, two patients developed 
crc (cumulative 5- year incidence 1.3%[95% ci 0% 
to 3.2%]). the 5- year an incidence was 44% (95% ci 
37% to 52%), and was lower for patients with SPS type 
iii (26%) than for patients diagnosed with type i (53%) 
or type i and iii (59%, p<0.001). Most patients were 
recommended a 2- year interval, and those recommended 
a 2- year interval were not at increased risk of an: an 
incidence after a 2- year recommendation was 15.6% 
compared with 24.4% after a 1- year recommendation 
(Or 0.57, p=0.08).
Conclusion risk stratification substantially reduced 
colonoscopy burden while achieving crc incidence 
similar to previous studies. an incidence is considerable 
in SPS patients, but extension of surveillance intervals 
was not associated with increased an in those identified 
as low- risk by the protocol. We identified SPS type iii 
patients as low- risk group that might benefit from even 
less frequent surveillance.
Trial registration number the study was registered 
on http://www. trialregister. nl; trial- iD ntr4609. 
InTroduCTIon
Serrated polyposis syndrome (SPS) is character-
ised by the presence of numerous colonic serrated 
polyps (SPs), and is accompanied by a substantially 
increased colorectal cancer (CRC) risk.1–4 Hence, 
close endoscopic surveillance is essential to prevent 
CRC development.1 2 5 Although previously consid-
ered to be uncommon, recent evidence estimates 
a prevalence of up to 1:111 (0.9%) individuals in 
faecal occult blood test- based screening cohorts and 
up to 1:238 (0.42%) in primary screening cohorts 
fulfil the diagnostic criteria for SPS diagnosis when 
subsequent surveillance colonoscopies are taken 
into account, making SPS the most prevalent polyp-
osis syndrome currently known.6–8 
Since no genetic mutations have been identi-
fied to diagnose SPS, diagnosis is based on clinical 
criteria defined by the WHO.5 These include (1) at 
significance of this study
What is already known on this subject?
 ► Serrated polyposis syndrome (SPS) is 
associated with a high prevalence of colorectal 
cancer (CRC), both at baseline as well as during 
surveillance.
 ► Endoscopic surveillance is needed to prevent 
CRC.
 ► Current surveillance recommendations might 
be too stringent for many SPS patients, but 
risk stratification tools are lacking.
What are the new findings?
 ► Extension of surveillance intervals is not 
associated with an increased incidence of 
advanced neoplasia.
 ► A substantial reduction in colonoscopy burden 
can be achieved by using patient- specific 
risk factors for determining optimal surveillance 
intervals.
How might it impact on clinical practice in the 
foreseeable future?
 ► Our proposed personalised surveillance 
protocol might help to achieve a substantial 
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Figure 1 Flow chart of surveillance protocol. *Clear colon of all polyps ≥5 mm, and all polyps <5 mm with the optical aspect of adenoma TSA or 
SSL. Thus, HPs 1–4 mm may be left in situ. HPs, hyperplastic polyp; SP, serrated polyp; SSL, sessile serrated lesion; TSA, traditional serrated adenoma.




The prevalence of CRC in patients with SPS has been esti-
mated to range between 15% and 35%.1 2 4 Two small cohorts 
reported a higher CRC incidence of 54%–70%.9 10 Although the 
majority of CRCs in SPS patients occur prior to, or at the time of 
SPS diagnosis, there also seems to be an increased risk for CRC 
during surveillance. In three retrospective and one prospective 
cohorts, the cumulative 5- year incidence of CRC under endo-
scopic surveillance ranged between 0% and 7.0%.1–4 11 This 
has led to stringent surveillance recommendations worldwide, 
most of them recommending either annual colonoscopy or 
colonoscopy every 1–2 years.12–15 For example, the US Multi- 
Society Task Force on CRC recommends annual surveillance 
colonoscopies for all SPS patients.12 Dutch and Spanish guide-
lines recommend surveillance every 1–2 years,13 16 but in daily 
practice, clinicians tend to stay on the safe side, with median 
surveillance intervals in recent cohort studies ranging between 
1.1 and 1.3 years.1–3 All guidelines mention the scarce evidence 
to support their stringent recommendations, and many authors 
have expressed the need for prospective evaluation of these 
surveillance recommendations.1–3 12
The prevalence of SPS combined with the stringent surveil-
lance regimens lead to substantial colonoscopy burden. Annual 
surveillance seems appropriate for some patients, but extension 
of surveillance intervals beyond 1 year might be safe for the 
majority. Unfortunately, current guidelines lack risk stratifica-
tion and are based on a one- size- fits- all principle.12–15 Several 
recent studies suggest that CRC risk depends on patient- 
specific risk factors, such as a history of advanced SP, advanced 
adenomas or smoking history.1–3 Ideally, such risk factors would 
facilitate personalised risk stratification and reduction of colo-
noscopy burden for patients at low risk of CRC. The importance 
of such risk stratification has been advocated by several authors 
recently.17 18
Therefore, the aim of the current study was to prospectively 
evaluate the safety and effectivity of a personalised surveillance 
protocol that uses individual patient characteristics to re- deter-
mine the optimal surveillance interval after each surveillance 
colonoscopy.
MeTHods
Patients and study design
All patients fulfilling WHO SPS criterion I and/or III5 were 
eligible for inclusion if they underwent endoscopic surveillance 
after successful clearing of all relevant polyps (see the Clearing 
phase section) between January 2013 and April 2018. To reflect 
a representative clinical setting, both SPS patients that already 
underwent surveillance before enrolment, as well as patients that 
had not undergone any surveillance before enrolment, could be 
included. Patients were recruited in three Spanish and six Dutch 
centres of expertise. Patients with a history of proctocolectomy 
or subtotal colectomy, with known CRC- related germline muta-
tions (ie, GREM, PTEN, BMPR1A, SMAD4, ENG1, (bi- allelic) 
MutYH or APC) or with inflammatory bowel disease were 
excluded. Individuals fulfilling only WHO criterion II were 
excluded from the current study because most experts agree that 
this criterion is insufficient for diagnosis of SPS, although litera-
ture supporting this claim is lacking. By excluding this group, we 
aimed to prevent potential contamination of our cohort with a 
subgroup of patients with a different CRC risk. Moreover, this 
was a prospective international multicentre cohort study. 
Because the surveillance protocol fell within the surveillance 
recommendations of Dutch and Spanish guidelines and data 
were collected as part of routine care, the Institutional Review 
Board of the Academic Medical Center Amsterdam decided that 
the study fell beyond the legislation regarding Medical Research 
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Figure 2 Flow chart of study inclusions. CRC, colorectal cancer; SPS, serrated polyposis syndrome.
Involving Human Subjects Act (Wet Medisch wetenschappelijk 
Onderzoek met mensen (WMO)). Patients were notified about 
the protocol verbally. The study was registered on the publicly 
accessible Dutch Trial Register (http://www. trialregister. nl; 
trial- ID NTR4609).
Histopathological evaluation
Tissue specimens were routinely processed by GI pathologists. 
SPs were classified as hyperplastic polyp, sessile serrated lesion 
(SSL, also known as sessile serrated adenoma or sessile SP) with 
or without dysplasia, or traditional serrated adenoma (TSA) 
based on the WHO classification for SP.5 19 Advanced adenomas 
were defined as adenomas ≥10 mm, with villous structure and/
or with high- grade dysplasia (HGD). Advanced SPs were defined 
as any SP >10 mm and/or with presence of dysplasia.
surveillance protocol
The protocol can be divided into two phases: the clearing phase 
and the surveillance phase. Surveillance colonoscopies that 
were scheduled during the study and according to the following 
protocol will from hereon be referred to as protocolised surveil-
lance. All surveillance that took place prior to study inclusion 
will from hereon be referred to as non- protocolised surveillance. 
A flow chart of the protocol is shown in figure 1.
Clearing phase
All patients underwent clearing with complete removal of all 
polyps ≥5 mm, and all polyps <5 mm with the optical aspect 
of an adenoma, SSL or TSA (thus, HPs 1–4 mm could be left in 
situ). If endoscopic clearing was not possible during one proce-
dure, colonoscopies were rescheduled within 6 months until all 
relevant polyps were removed. A new colonoscopy was also 
re- scheduled in case the cecum was not intubated and/or when 
the Boston Bowel Preparation Score was below 6. Patients that 
had been cleared before the start of this study could be included 
as well, in case the last recorded clearing colonoscopy was 
performed according to the above- mentioned quality criteria.
Surveillance phase
During surveillance, all polyps ≥5 mm and all polyps <5 mm 
with the optical aspect of an adenoma or SSLs were removed 
(HPs 1–4 mm could be left in situ). Each surveillance colonos-
copy was scheduled with an interval of either 1 or 2 years, based 
on the findings at the previous endoscopy (figure 1). Thus, the 
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Table 1 Baseline characteristics for the 271 included patients
Age at diagnosis SPS, mean (SD) 60 (10)
Age at start of prospective follow- up, mean (SD) 62 (9)
Male, n (%) 130 (48%)
Reason first colonoscopy, n (%)
  FOBT- based screening 79 (29%)
  Primary colonoscopy screening 14 (5.2%)
  Familial CRC risk 36 (13%)
  Symptoms 110 (41%)
   Pain/discomfort abdomen 27/110 (25%)
   Rectal blood loss 29/110 (26%)
   Altered defecation pattern 29/110 (26%)
   Anaemia 6/110 (5.5%)
   Unexplained weight loss 2/110 (1.8%)
  Other/unknown 32 (12%)
Family history
  ≥1 FDR with CRC, n (%*) 85/250 (34%)*
  ≥1 FDR with SPS (WHO 1 and/or 3), n (%*) 11/256 (4.3%)*
WHO SPS classification at inclusion, n (%)
  I 99 (36.5%)
  III 99 (36.5%)
  I and III 73 (27%)
CRC prior to protocolised surveillance phase, n (%) 67 (25%)
  Age at diagnosis, median (range)† 61 (19–79)
  Multiple CRC, n (%) 16 (24%)
   Synchronous 9/16 (56%)
   Metachronous 6/16 (37.5%)
   Synchronous and metachronous 1/16 (6.2%)
Moment of CRC diagnosis, n (%)†
  Prior to clearing phase 40/67 (60%)
  During clearing phase 27/67 (40%)
  During surveillance, but prior to study inclusion 0
Total number of colonoscopies prior to clearing 523
  Per patient, median (range) 1 (0–15)
Total number of clearing colonoscopies 543
  Per patient, median (range) 2 (1–9)
Total no. of surveillance colonoscopies prior to inclusion 202
  Per patient, median (range) 0 (0–7)
Total number of prospective protocolised surveillance 
colonoscopies
570
  Per patient, median (range) 2 (1–5)
Total years of prospective follow- up 942 patient- years
  Per patient, median (IQR) 3.6 (2.3–4.9)
*Percentage refers to patients for whom variable was available.
†In case patients had multiple (metachronous) CRCs, these values refer to the first 
CRC.
CRC, colorectal cancer; FDR, first- degree relative; FOBT, faecal occult blood test; SPS, 
serrated polyposis syndrome.
recommended surveillance interval for each patient could vary 
based on the findings of each subsequent surveillance colonos-
copy (figure 1). In case of multiple colonoscopies in the same 
surveillance phase (eg, because of poor bowel preparation, 
incomplete colonoscopy or multiple colonoscopies due to polyp 
burden), detected lesions from all colonoscopies were accumu-
lated to determine the subsequent surveillance interval.
Patients were recommended a surveillance interval of 1 year 
in case one or more advanced SPs or adenomas were removed, 
if cumulatively ≥5 relevant polyps were removed (SSL [irrespec-
tive of size] and/or adenomas [irrespective of size] and/or HPs 
≥5 mm), or if surgery was needed during the last surveillance/
clearing phase. In all other cases, a 2- year surveillance interval 
was recommended.
The criteria used in this protocol were chosen based on 
the consensus of the authors, since no risk factors had been 
established at the time this protocol was drafted in 2012.
Protocol violation
Protocol violation was defined as a deviation from the required 
surveillance interval of ≥365 days. In case of violation of the 
surveillance protocol, only the data prior to the protocol viola-
tion were used for our analyses, and the patient was censored 
at the moment the surveillance colonoscopy should have taken 
place.
Colonoscopy quality
All procedures were performed using standard or high- definition 
white light endoscopy at dedicated endoscopy programmes. 
Advanced imaging techniques (eg, [virtual] chromoendos-
copy and Endocuff) were not routinely used, but could be used 
based on the preference of the endoscopist. Bowel preparation 
was performed according to local practice.
study endpoints and statistical analyses
Primary endpoint was the cumulative 5- year incidence of CRC 
alone as well as of advanced neoplasia (AN) (CRC, advanced SP 
or advanced adenoma), calculated using Kaplan- Meier analyses. 
All risk factors identified in previous studies (smoking, WHO 
criteria, previously diagnosed with SPs proximal to the splenic 
flexure, SPs with dysplasia, advanced SPs, advanced adenomas, 
synchronous large SP and advanced adenoma, and age at SPS 
diagnosis), as well as history of CRC, were assessed in univariate 
and multivariable (adjusted for age, gender and smoking status) 
Cox regression analysis and were presented as HR with 95% 
CI.1–3 20 A multivariate model was used to perform multiple 
imputations to adjust for missing variables.
Secondary outcomes were the frequency of 1- year and 2- year 
surveillance recommendation and the incidence of conversion 
to colorectal surgery during the surveillance phase. The risk of 
AN after a 1- year recommendation was compared with the risk 
of AN after a 2- year recommendation using logistical regression 
analysis, expressed as OR. Survival curves were produced using 
RStudio V.1.1.453 (Integrated Development for R. RStudio, 
Inc., Boston, MA, USA) with survminer package version V.0.4.3. 
All other analyses were performed using SPSS V.24.
resulTs
study flow and patient characteristics
Between January 2013 and April 2018, 554 SPS patients were 
identified in patient registries of the participating centres, and 
were assessed for eligibility (figure 2). After review, 141 patients 
did not meet our inclusion and exclusion criteria and were, thus, 
excluded. Eighty- five patients had to be excluded because they 
were enrolled too late and thus, their first surveillance was sched-
uled after study closure. Furthermore, patients were excluded 
because they did not receive any colonoscopy within the study 
timeframe (31), because of systematic protocol violation (22) or 
because their colon was not yet completely cleared (4).
The 271 included patients were followed for a median of 
3.6 years (IQR 2.3–4.9 years). Mean age at the start of proto-
colised surveillance was 60 years (±10), and 130 (48%) were 
male (table 1). At study inclusion, 99 patients (36.5%) fulfilled 
WHO criterion I; 99 (36.5%) fulfilled criterion III and 73 (27%) 
fulfilled criterion I and III. Prior to protocolised surveillance, 67 
 o
n
 February 28, 2020 at University of G
roningen. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2018-318134 on 13 April 2019. Downloaded from 
116 Bleijenberg agc, et al. Gut 2020;69:112–121. doi:10.1136/gutjnl-2018-318134
Colon
Figure 3 Dynamics of surveillance recommendation 1 year versus 2 years in surveillance round 1–3. Circles represent the proportion of patients 
in surveillance round 1, 2 and 3 that received a 1- year or 2- year surveillance recommendation. The arrows show the proportion of patients that 
are recommended the same (horizontal arrows) or a different (diagonal arrows) surveillance interval during subsequent round of surveillance. For 
example, 79% of the patients recommended a 2- year interval in round 1 are also recommended a 2- year interval in round 2.
patients (25%) were diagnosed with CRC, of whom nine had 
synchronous CRC, six had metachronous CRC and one had 
both synchronous and metachronous CRC.
Of the 271 included patients, 84 (31%) had already under-
gone surveillance before inclusion while the remaining 69% 
underwent their first surveillance endoscopy during follow- up. 
The majority of patients received a 2- year surveillance recom-
mendation, which increased from 52% after the first surveillance 
colonoscopy to 71% after the third surveillance colonoscopy 
(figure 3). A 2- year interval in the first and second surveillance 
round was followed by another 2- year interval in 79% and 87% 
of patients, respectively.
All patients underwent at least one protocolised surveillance 
colonoscopy, which was followed by a second, third, fourth and 
fifth surveillance colonoscopy in 173, 66, 15 and 1 patients, 
respectively. Protocol violation led to early dropout in seven 
patients. A detailed overview of relevant findings during surveil-
lance colonoscopies is presented in table 2.
CrC under protocolised surveillance
Two patients were diagnosed with CRC while under protoco-
lised endoscopic surveillance, corresponding to a cumulative 
5- year CRC incidence of 1.3% (95% CI 0% to 3.2%, figure 4A). 
The CRCs occurred in surveillance phase 2 and 3, respectively. 
Detailed characteristics are presented in online supplemen-
tary table 1. Briefly, the first CRC occurred 1 year after piece-
meal removal of a tubulovillous adenoma with HGD, and was 
preceded by a scar inspection 6 months earlier during which 
the scar could not be located. The second CRC occurred after 
a 2- year recommendation. It protruded from inside an anasto-
mosis of an earlier right- sided hemicolectomy, and histologically 
and endoscopically appeared to be a local recurrence of a CRC 
that had been resected 6 years earlier.
An under protocolised surveillance
The cumulative 5- year incidence of AN during follow- up was 
44% (95% CI 37% to 51%, figure 4B). The risk of devel-
oping AN during follow- up was strongly associated with WHO 
subtype: 53% (95% CI 39% to 65%), 26% (95% CI 16% to 
35%) and 59% (95% CI 40% to 72%) for WHO I, III, and I and 
III, respectively. Compared with patients diagnosed with WHO 
I, patients fulfilling WHO III had a HR of 0.38 (95% CI 0.22 
to 0.63, p<0.001) for developing AN. Adjusted for age at inclu-
sion, smoking status and gender, the HR remained unchanged 
(table 3 and figure 4C). Patients fulfilling only WHO criterion I 
had the same risk as patients diagnosed with both WHO criteria 
I and III (HR 0.91, 95% CI 0.58 to 1.43, p=0.68).
None of the other previously identified CRC risk factors 
(gender, smoking status, advanced adenoma, SP with dysplasia, 
advanced SP, large SP with synchronous advanced adenoma, SP 
proximal to the splenic flexure or previous history of CRC) were 
associated with the risk of developing AN during surveillance 
in univariate and multivariable analyses (table 3 and figure 4D).
Because patients that received surveillance prior to study inclu-
sion might have a different risk of AN than those that received 
their first surveillance during our study, we performed additional 
sensitivity analyses. These showed that patients that had received 
one or more surveillance colonoscopies prior to study inclusion 
had a slightly lower risk of developing AN during our study than 
patients that received their first surveillance during our study 
(HR 0.64, 95% CI 0.41 to 0.99; p=0.047)
An after a 1-year versus 2-year surveillance interval
In 255 occasions, a surveillance recommendation according to 
our protocol was followed by a subsequent surveillance endos-
copy. AN was detected in 31 of 127 (24.4%) colonoscopies that 
were performed after a 1- year surveillance recommendation, 
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Patients with CRC, n (%) 69 (25%) 0 0 1 1 0 0
Patients with ≥1 polyp 271 (100%) 81 214 (79%) 132 (76%) 56 (85%) 15 (100%) 1
  Number of polyps per patient, median 
(range)
22 (1–157) 8 (0–39) 3 (0–19) 2 (0–20) 2 (0–13) 3 (1–9) 2
  Patients with ≥1 advanced polyp† 237 (87%) 25 (30%) 73 (27%) 31 (18%) 12 (8%) 6 (40%) 0
Patients with at least one:
  Any SP 271 (100%) 78 (93%) 195 (72%) 121 (70%) 45 (68%) 13 (87%) 1
  HP 249 (92%) 77 (92%) 148 (55%) 83 (48%) 25 (38%) 11 (73%) 0
  SSL 215 (79%) 37 (44%) 106 (39%) 64 (37%) 27 (41%) 4 (27%) 0
  TSA 15 (5.9%) 4 (5%) 1 (0.4%) 2 (1.2%) 1 (1.5%) 0 0
  SP ≥10 mm 192 (71%) 13 (16%) 58 (21%) 28 (16%) 7 (11%) 4 (27%) 0
  SP with dysplasia 61 (23%) 7 (8%) 7 (3%) 5 (2.9%) 5 (8%) 0 0
Median number of SP per patient (range):
  Any SP 17 (1–116) 6 (0–31) 2 (0–17) 2 (0–20) 1.5 (0–13) 2 (0–8) 2
  HP 9 (0–114) 4 (0–31) 1 (0–13) 0 (0–10) 0 (0–8) 1 (0–7) 0
  SSL 4 (0–55) 0 (0–23) 0 (0–15) 0 (0–11) 0 (0–13) 0 (0–3) 0
  TSA 0 (0–7) 0 (0–5) 0 (0–6) 0 (0–1) 0 (0–1) 0 (0–0) 0
  SP ≥10 mm 2 (0–25) 0 (0–5) 0 (0–7) 0 (0–4) 0 (0–3) 0 (0–2) 0
  SP with dysplasia 0 (0–14) 0 (0–5) 0 (0–6) 0 (0–2) 0 (0–3) 0 (0–0) 0
Patients with at least one adenoma: 216 (80%) 58 (69%) 113 (42%) 60 (35%) 21 (32%) 7 (47%) 0
  Advanced adenoma ‡ 131 (48%) 8 (9%) 20 (7.4%) 3 (2.3%) 1 (1.5%) 2 (13%) 0
Median number of adenomas per patient 3 (0–41) 1.5 (0–16) 0 (0–10) 0 (0–8) 0 (0–8) 0 (0–4) 0
  Advanced adenoma 0 (0–7) 0 (0–1) 0 (0–2) 0 (0–2) 0 (0–1) 0 (0–1) 0
*This column represents only one patient. Therefore, no median or range is given.
†Advanced polyp: advanced adenoma (≥25% villous histology, high- grade dysplasia and ≥10 mm in diameter)/advance.
‡Advanced adenoma: ≥25% villous histology, high- grade dysplasia and ≥10 mm in diameter.
CRC, colorectal cancer; HP, hyperplastic polyp; FDR, first- degree relative; FOBT, faecal occult blood test; SP, serrated polyp; SPS, serrated polyposis syndrome; SSL, sessile serrated 
lesion; TSA, traditional serrated adenoma.
compared with 20 of 128 (15.6%) colonoscopies performed 
after a 2- year surveillance recommendation (OR 0.57, 95% CI 
0.31 to 1.07, p=0.08). Incidence of other polyp subtypes after 
1- year versus 2- year recommendation is displayed in online 
supplementary table 2.
surgery
During protocolised surveillance, surgery was required in three 
patients. The first patient underwent laparotomy and adhesi-
olysis because of bowel obstruction due to previous surgery. The 
other two patients underwent a proctocolectomy and subtotal 
colectomy, respectively, both because of CRC. Both had under-
gone a right- sided hemicolectomy for CRC in the past. No 
surgery was performed for the indication polyp burden or a 
single endoscopically unresectable polyp.
dIsCussIon
In this large prospective cohort study, we assessed the safety and 
effectivity of an individualised surveillance protocol for patients 
diagnosed with SPS. Our protocol showed to be effective in 
decreasing colonoscopy burden while at the same time achieving 
low incidence of CRC. During a median follow- up of 3.6 years, 
the cumulative 5- year incidence of CRC was 1.3%, which is 
similar to the incidence reported in recent studies,1 6 21 and lower 
than incidence rates in two retrospective cohort studies.3 4 In 
comparison, this incidence rate is identical to that of a regular 
postpolypectomy population after resection of intermediate- risk 
adenomas.22 The cumulative 5- year incidence of AN, on the 
other hand, was high (44%) and strongly associated with WHO 
subtype. Patients diagnosed with WHO criterion I or I and III 
were more than twice as likely to develop AN during surveillance 
compared with patients diagnosed with WHO criterion III only. 
The use of our protocol seems safe and effective with little need 
for surgical intervention. After three consecutive surveillance 
colonoscopies, two- thirds of the patients were appointed 2- year 
surveillance intervals according to the protocol. The extended 
2- year interval did not result in an increased incidence of AN. 
Indeed, a non- significant trend was seen for a lower risk of AN 
after a 2- year recommendation (OR 0.57, p=0.08)
The high AN incidence confirms that close endoscopic surveil-
lance of SPS patients is warranted.3 However, we believe (more) 
stringent surveillance than the regimen described by our surveil-
lance protocol will not further reduce CRC incidence. After all, 
one of the two CRCs that occurred during our study occurred 
after a surveillance recommendation of 1 year. The other CRC, 
occurring after a 2- year recommendation, was a local recur-
rence protruding from inside the anastomosis. Although more 
stringent surveillance could have led to earlier detection of this 
recurrence, it would not have been prevented. Since none of the 
CRCs in our cohort can, thus, be attributed to the lengthened 
surveillance intervals, extension of the surveillance interval to 
2 years based on our protocol seems safe and feasible. The US 
guidelines recommend annual surveillance,12 and although 
European guidelines generally recommend surveillance every 
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Figure 4 Cumulative 5- year incidence of CRC (A) and advanced neoplasia (B–D). The p value displayed in panel C and D was calculated using a 
log- rank test, comparing all WHO subtypes (panel C) and smoking behaviour (panel D). AN, advanced neoplasia (defined as CRC, advanced adenoma 
or advanced SP); CRC, colorectal cancer; SP, serrated polyp.
1–2 years, reported median surveillance intervals range from 1.1 
to 1.3 years.1–3 As our protocol predominantly led to a 2- year 
surveillance recommendation, a substantial reduction in colo-
noscopy burden could be achieved compared with current prac-
tice. As a comparison, in case annual surveillance would have 
been provided in our cohort, about 942 colonoscopies would 
have been performed during the 942 patient- years of prospec-
tive follow- up. Using our protocol, however, only 570 colonos-
copies were performed, which means about 372 (39%) fewer 
colonoscopies were performed using our protocol compared 
with annual surveillance. Further improvement of risk stratifica-
tion should aim to further reduce colonoscopy burden without 
increasing AN risk. However, no ‘acceptable’ incidence of 
AN per surveillance colonoscopy has been established for SPS 
patients. Although our study might provide benchmarks in this 
regard, the incidence rate that should trigger early surveillance 
can be debated. Some might argue that surveillance intervals can 
be extended up until a point where SPS patients have an AN inci-
dence of 30% or even 40%, whereas others would rather shorten 
surveillance intervals until AN incidence would be below 15%. 
In our study, we found an AN incidence of 24.4% following a 
1- year interval and 15.6% after a 2- year interval. Comparably, a 
recent large retrospective cohort study reported an average AN 
incidence of 24% per surveillance colonoscopy.3 Taken together, 
this suggests AN incidence rates of 20%–25% per surveillance 
colonoscopy might be inevitable.
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Table 3 Risk factors for time to advanced neoplasia during follow- up
Advanced neoplasia during surveillance univariate Hr
(95% CI) P value
Multivariable 
Hr* (95% CI) P valueno Yes
Gender, n (%)
  Male 83 (64%) 47 (36%) 1 1
  Female 90 (64%) 51 (36%) 0.95 (0.64 to 1.41) 0.81 0.99 (0.66 to 1.50) 0.97
Smoking status
  Never smoker 56 (70%) 24 (30%) 1 1
  Former smoker 46 (65%) 25 (35%) 1.22 (0.71 to 2.08) 0.48 1.20 (0.68 to 2.13) 0.52
  Current smoker 58 (69%) 26 (31%) 1.10 (0.62 to 1.95) 0.75 1.09 (0.61 to 1.95) 0.76
WHO criterion at study inclusion†
  WHO I 56 (57%) 43 (43%) 1 1
  WHO III 77 (78%) 22 (22%) 0.38 (0.22 to 0.63) <0.001 0.38 (0.22 to 0.64) <0.001
  WHO I and III 40 (55%) 33 (45%) 0.91 (0.58 to 1.43) 0.68 0.89 (0.56 to 1.40) 0.6
Age at SPS diagnosis 0.98 (0.96 to 1.01) 0.15 0.99 (0.96 to 1.01) 0.16
≥1 advanced adenomas‡
  No 93 (66%) 47 (34%) 1 1
  Yes 80 (61%) 51 (39%) 1.21 (0.82 to 1.80) 0.34 1.24 (0.82 to 1.87) 0.31
≥1 advanced SP‡
  No 45 (69%) 20 (31%) 1 1
  Yes 128 (62%) 78 (38%) 1.46 (0.89 to 2.39) 0.13 1.46 (0.89 to 2.40) 0.13
≥1 SP proximal to splenic flexure†
  No 27 (59%) 19 (41%) 1 1
  Yes 146 (65%) 79 (35%) 0.84 (0.51 to 1.38) 0.49 0.86 (0.51 to 1.43) 0.95
≥1 SP with dysplasia‡
  No 131 (62%) 79 (38%) 1 1
  Yes 42 (69%) 19 (31%) 0.82 (0.50 to 1.36) 0.44 0.84 (0.51 to 1.39) 0.5
≥1 SP≥10 mm and ≥1 advanced adenoma‡
  No 167 (65%) 91 (35%) 1 1
  Yes 6 (46%) 7 (54%) 1.270 (0.59 to 2.74) 0.54 1.21 (0.56 to 2.64) 0.63
CRC‡
  No 131 (64%) 73 (36%) 1 1
  Yes 42 (63%) 25 (37%) 1.14 (0.74 to 1.80) 0.56 0.80 to 2.07 0.31
*Adjusted for potential confounders: age, gender and smoking status.
†WHO criterion I: ≥5 SP proximal to sigmoid colon with at least two being ≥10 mm in diameter; WHO criterion III: ≥20 SP of any size, spread throughout the colon.5
‡Diagnosed prior to or during clearing phase.
CRC, colorectal cancer; SP, serrated polyp; SPS, serrated polyposis syndrome.
To further improve risk stratification, we assessed risk factors 
that have previously been identified (smoking status, age at 
inclusion, fulfilment of WHO criterion I and III, previous diag-
nosis of an advanced adenoma, advanced SP, synchronous large 
SP and advanced adenoma, SP proximal to the splenic flexure or 
an SP with dysplasia).1–3 20 Fulfilment of WHO criterion III was 
inversely associated with a patient’s risk of AN during follow- up. 
This association was remarkably strong, and might suggest that 
surveillance intervals can be extended for patients that solely 
fulfil WHO criterion III. None of the other risk factors was asso-
ciated with AN during surveillance in our cohort. This could 
be explained by the fact that the studies that initially identi-
fied these risk factors assessed their association with a history 
of CRC. Almost all CRCs included in those analyses occurred 
prior  to  surveillance. In contrast, in our study, we assessed 
the association between these risk factors and the risk of AN 
during surveillance. The incongruence between our and previous 
findings suggests that risk factors associated with CRC before 
surveillance are not necessarily applicable for the risk of devel-
oping AN during surveillance. However, although our cohort 
is large compared with other studies on SPS, it is still relatively 
small, and perhaps was not powered to detect subtle correlations 
between the assessed risk factors and AN.
We believe our study has several strengths. First of all, we 
describe the largest prospective cohort of SPS patients to date, 
and this study was the first to assess a personalised surveil-
lance protocol for SPS patients, allowing risk stratification for 
a mixed population with a variable CRC risk. As surveillance 
guidelines are currently based on low- quality evidence, many 
authors have expressed the urge of such prospective evaluation 
of surveillance.1–3 12 Our study now provides an evidence- based 
surveillance strategy for SPS patients, which could be of help 
to establish future surveillance guidelines. The international 
multicenter design, as well as the fact that both academic and 
non- academic centres were included, warrants a good external 
validity. Nonetheless, several limitations have to be acknowl-
edged as well. First, our median follow- up duration of 3.6 years 
might be considered short to monitor CRC occurrence. Longer 
follow- up with more rounds of surveillance is needed to assess 
the long- term CRC incidence. Second, with only two cases of 
CRC during surveillance, we were not able to assess risk factors 
for the development of CRC during surveillance because the 
sample size required for such analyses would be a multitude of 
our study population. Nonetheless, we were able to evaluate risk 
factors for AN during follow- up, which is likely to be strongly 
associated with one’s risk of developing CRC. Third, some 
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patients received only one protocolised surveillance colonoscopy, 
whereas others received five. The more colonoscopies a patient 
underwent during the 5- year study period, the more likely it is 
that he or she received several 1- year surveillance recommen-
dations instead of 2- year surveillance recommendations, owing 
to advanced polyps or a high number of non- advanced polyps. 
Therefore, the patients that underwent colonoscopies in surveil-
lance phase 3, 4 or 5 are predominantly high- risk patients that 
have a tendency to harbour advanced findings. The described 
prevalence of (advanced) polyps in surveillance phase 3–5 
(table 2) might, therefore, be inflated due to confounder by indi-
cation. However, because our survival analyses were not influ-
enced by the number of surveillance colonoscopies, our main 
outcome measures were not affected by such bias. Finally, some 
of the patients enrolled in our study (31%) had already received 
one or more surveillance colonoscopies prior to study inclusion. 
This is relevant, since AN incidence seemed to decrease after 
several rounds of surveillance, which can be seen in table 2 and 
figure 3B. Patients that already underwent surveillance prior to 
study inclusion could, therefore, be expected to have a lower AN 
incidence than patients that underwent their first surveillance 
as part of the study. This effect was confirmed in a sensitivity 
analysis: patients with surveillance prior to study inclusion were 
at lower risk of AN than patients without surveillance prior to 
study inclusion (HR 0.64, 95% CI 0.41 to 0.99, p=0.047). Since 
the majority (69%) of our cohort did not undergo surveillance 
prior to inclusion, we expect this effect has not substantially 
influenced our results. Nonetheless, a slightly higher AN inci-
dence than reported here might be expected in a population 
without previous surveillance.
All in all, our results suggest that the proposed surveillance 
protocol can safely be implemented for SPS patients without 
risking an increase in CRC incidence. Future studies should 
aim to reduce the colonoscopy burden in true low- risk patients 
even further. Since a 2- year recommendation was not associated 
with increased AN incidence, perhaps further extension beyond 
2 years might be safe for these patients as well. Our results, 
furthermore, indicate that patients that only fulfil WHO crite-
rion III might be a group of low- risk, and possibly a 3- year or 
even a 5- year surveillance interval might be safe for this group. 
However, it is important to note that SPS patients are a group 
of high- risk patients, and an extension of surveillance intervals 
from the currently studied protocol should be done with caution 
and be part of prospective studies in expert centres.
In conclusion, in this largest prospective cohort of SPS patients 
to date, we present and assessed a new personalised surveillance 
strategy for the treatment and surveillance of this prevalent 
disease. While achieving a substantial reduction of colonoscopy 
burden, CRC incidence in our cohort was similar to most previ-
ously reported incidence rates. Our protocol will likely lead to 
a substantial reduction in colonoscopy burden. Future efforts 
will be made to further reduce colonoscopy burden, especially 
for patients only fulfilling WHO criterion III.
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